Abstract
Evidence-based Clinical Guidelines (CGs) for Good Clinical Practice (GCP) have emerged to synthesize and systematize a wealth of knowledge from scientific journals that health professionals have been unable to follow. Today, the COVID 19 pandemic requires them more than ever. CGs are defined as a set of systematized claims, based on a systematic analysis of scientific evidence, that point to the performance of GCP; contain an assessment of the usefulness and harmfulness of various diagnostic and therapeutic options. "The Good": CG is necessary for health professionals, patients and society, because the knowledge gained in studies is insufficient to perform GCP in further practice. "The Bad": The shortcomings of the CG stem from; (a) there are still many unknowns in medicine, as funding for scientific research is inadequate; (b) the disunity of different institutions that make recommendations at the global, even local level results in different guidelines, although they are based on identical scientific papers as evidence; (c) most clinical scientific studies exclude groups of patients that make up a significant population in everyday practice and the guidelines more or less (do not) apply to them; (d) the impossibility of implementing the CG, because they are not backed by state regulatory bodies and / or the economy cannot follow them. "The Ugly": (a) the ambition of a large number of practitioners and researchers to be among the authors of the guidelines, although many do not have competence for the subject matter; (b) industry (equipment, drugs, supplements) most often funds scientific research and the interdependence of industry and the "dependence" of the authors of guidelines is often intertwined; and (c) publishing (un) intentionally falsified study results which then serve to "support" some guidelines. often in (un) intentional alliance with the editors of the world's elite medical journals.
Publisher
Centre for Evaluation in Education and Science (CEON/CEES)